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Deducing signaling pathways from 
parallel actions of arsenite and 
antimonite in human epidermal 
keratinocytes
Marjorie A. phillips1, Angela cánovas2, Miguel A. Rea3, Alma islas-trejo4, Juan f. Medrano4, 
Blythe Durbin-Johnson5, David M. Rocke5 & Robert H. Rice1*
Inorganic arsenic oxides have been identified as carcinogens in several human tissues, including 
epidermis. Due to the chemical similarity between trivalent inorganic arsenic (arsenite) and antimony 
(antimonite), we hypothesized that common intracellular targets lead to similarities in cellular 
responses. Indeed, transcriptional and proteomic profiling revealed remarkable similarities in 
differentially expressed genes and proteins resulting from exposure of cultured human epidermal 
keratinocytes to arsenite and antimonite in contrast to comparisons of arsenite with other metal 
compounds. These data were analyzed to predict upstream regulators and affected signaling pathways 
following arsenite and antimonite treatments. A majority of the top findings in each category were 
identical after treatment with either compound. inspection of the predicted upstream regulators led 
to previously unsuspected roles for oncostatin M, corticosteroids and ephrins in mediating cellular 
response. The influence of these predicted mediators was then experimentally verified. Together 
with predictions of transcription factor effects more generally, the analysis has led to model signaling 
networks largely accounting for arsenite and antimonite action. the striking parallels between 
responses to arsenite and antimonite indicate the skin carcinogenic risk of exposure to antimonite 
merits close scrutiny.
Chronic exposure to inorganic arsenic, primarily in water supplies, has numerous deleterious effects on humans, 
including cancer at several anatomic sites1. Many mechanisms have been proposed for these effects, indicating 
possible interference of arsenic with a variety of signaling pathways2 to which epigenetic changes may contribute3. 
Proteins with vicinal thiols, including zinc finger DNA repair proteins4, are particularly attractive as potential 
targets with deleterious downstream effects. Continuing exposure of large populations has evoked considerable 
effort to elucidate the broad consequences for health and the mechanisms that lead to their manifestation.
Also of concern, including human therapeutic treatment for leishmaniasis5, considerable exposure occurs to 
inorganic antimony, a metalloid immediately below arsenic in the periodic table to which it exhibits chemical 
similarity6. The presence of antimony is increasing in the environment through use in small arms ammunition, 
as a catalyst in plastic, as a flame retardant, and through watershed pollution by mining waste or by recycling 
operations. This has raised concern for public health, sustainable agriculture and ecosystem effects7,8. Inasmuch 
as antimony trioxide is a rodent carcinogen9, finding commonalities in actions of antimonite (SbIII) and arsenite 
(AsIII) would assist in understanding their mechanisms of action in vivo.
Human epidermis is a known target for carcinogenic effects of arsenic. Cultured human epidermal kerati-
nocytes, a model system for studies of effects of chemicals on epidermis, have been shown to respond similarly 
to treatment with arsenite and antimonite. As shown using the normal cells and a minimally deviated line of 
spontaneously immortalized human epidermal keratinocytes (SIK), both metalloids suppress many aspects of 
the cell differentiation program while preserving the proliferative potential of the cells10–13. Recently, protein 
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and transcriptional profiling experiments using SIK demonstrated that changes due to treatment with these two 
agents occur in parallel14. The initial targets and mechanisms of action, and how similar these are for arsenite and 
antimonite, remain to be determined. For this purpose, we have analyzed profiling data to predict cell signaling 
pathways and transcription factors that appear to mediate downstream effects. Global analyses of changes in 
proteins and mRNAs now permit a more general approach to the identification of signaling pathways and tran-
scription factors that drive the responses. As a result, three previously unsuspected signaling pathways for these 
metalloids have been revealed and validated in keratinocytes, and model signaling networks largely accounting 
for arsenite and antimonite action are presented.
Results
parallel changes in transcript and protein levels. Applying the parameters p < 0.05 and fold change 
>2, 387 and 598 differentially expressed mRNAs were identified between untreated (control) and arsenite or anti-
monite treatments, respectively, while the number of differentially expressed mRNAs comparing samples from 
arsenite- and antimonite-treated cells was 49, an order of magnitude fewer. This relationship, consistent with our 
previous report14, can be visualized as a scatterplot of log fold change of genes differentially expressed after arsen-
ite treatment vs. log fold change of those genes after antimonite treatment (Fig. 1A). Not previously recognized, 
the present analysis reveals that the 49 genes differing in their transcriptional responses to arsenite and antimo-
nite also show a strong concordance of response. The basis of their difference was sensitivity; approximately half 
were more responsive to arsenite and the other half were more responsive to antimonite (Fig. 1B). A scatterplot of 
differentially expressed proteins identified in our earlier study also shows a high level of concordance of responses 
to arsenite and antimonite (Fig. 1C).
Emphasizing the remarkable concordance of response between arsenite and antimonite, transcriptional 
responses to arsenite were not parallel with responses to several metal compounds. Although arsenate and 
arsenite responses were concordant in our DNA microarray studies15, such studies showed poor concordance in 
response to arsenic treatment compared to cadmium, chromate or vanadate (Fig. 1D–F), not previously reported.
pathway analysis. Using the lists of differentially expressed genes identified here and proteins identified 
in our earlier study, Ingenuity Pathway Analysis (IPA) software was used to explore signaling pathways and 
upstream regulators resulting from arsenite and antimonite exposure. Results indicate that arsenite and anti-
monite produce similar effects in keratinocytes because they target many of the same metabolic pathways and 
regulators, leading to significant overlap in differentially expressed genes and proteins.
Canonical pathways. Based on analysis of differentially expressed genes, Table 1A shows the merged five top 
pathways enriched for genes affected by arsenite or antimonite treatment and the numbers of genes on which 
the predictions are based. Four of these predicted pathways are identical (Nrf2-mediated oxidative stress, gluco-
cortcoid receptor signaling, xenobiotic metabolism signaling, γ-glutamyl cycle), while vitamin C transport is in 
the top five only for antimonite treatment, and retinoate biosynthesis is affected only by arsenite treatment. As 
seen in the full list of genes employed in the analysis (Supplementary Table S1), many of the same genes (76%) 
are included on lists of both arsenite-affected and antimonite-affected genes. The genes responsible for effects on 
Nrf2-mediated oxidative stress response, xenobiotic metabolism signaling, vitamin C transport and γ-glutamyl 
cycle pathways overlap substantially with each other, likely all a result of Nrf2 (NFE2L2) activation. Proteomic 
analysis also predicted the involvement of the Nrf2-mediated oxidative stress response as a top affected pathway 
(Table 1B).
Predicted upstream regulators. The list of top five regulators, predicted by analysis of differentially expressed 
genes due to arsenite and antimonite treatments, overlap for four of the top five predicted molecules (Table 2A). 
Two of these are expected as upstream regulators of arsenite effects: arsenite itself and NFE2L2 (Nrf2), a tran-
scription factor induced by arsenite treatment, and both are predicted to be activated. The predicted activation of 
these two regulators after antimonite treatment also provides strong support for the hypothesis that arsenite and 
antimonite overlap in their mechanisms.
The identification of dexamethasone as an upstream regulator in keratinocytes is consistent with well-known 
clinical effects of corticosteroids in dermatology and with the identification of glucocorticoid signaling as an 
enriched canonical pathway. The identification of oncostatin M (OSM) and tumor necrosis factor alpha (TNFα) 
may help to explain keratinocyte-specific effects since these cytokines are known to target this cell type16,17. Sorted 
by z score (activation score), 45 and 85 regulators are predicted to be activated by arsenite and antimonite, respec-
tively (24 in common), and 33 and 30 predicted to be inhibited (11 in common) (Supplementary Tables S2 and 
S3). Top shared inhibited regulators are NRG1 (an EGF receptor family ligand), and isotretinoin (13-cis retinoic 
acid), both of which have complex effects on keratinocyte proliferation and differentiation18–20. Other predicted 
inhibited regulators were calcium ion, EFNA1 and FGF10, all reported to increase expression of several markers 
of keratinocyte differentiation21–23. The transcription factor DDIT3 and signaling molecules KRAS and STAT4 are 
also predicted to be activated by both agents.
The predicted activities of upstream regulators show remarkable similarity for arsenite and antimonite treated 
samples, as displayed in a heat map of top regulators (sorted by p value) (Supplementary Fig. S1A). Filtering the 
results for genes, proteins and RNAs to eliminate exogenous chemicals (Supplementary Fig. S1B) showed that the 
main difference is TNFα (predicted to be activated by antimonite, but not arsenite).
The list of top five upstream regulators predicted by proteomic analysis (Table 2B) differs from those predicted 
by transcriptional analysis, although most appear as lower-ranked entries on the latter. Three of these top reg-
ulators appear on both arsenite and antimonite lists: Myc, EFNA4 and ROCK2. All of these have demonstrated 
effects on keratinocyte differentiation and proliferative potential. Sorted by z score, five and seventeen regulators 
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were predicted to be activated by arsenite and antimonite, respectively (three in common: NFE2L2, GLI2 and 1,2- 
dithiol-3-thione, an activator of NFE2L2) and thirteen and sixteen, respectively, were predicted to be inhibited 
(eight in common: ROCK2, GLIS1, EFNA1, 2, 3,and 4, TNFSF11 and isotretinoin).
Overall, these predicted upstream regulators from analysis of arsenite and antimonite treated samples display 
extensive overlap and suggest potential shared targets for exploration to explain downstream effects. The impact 
of arsenite on NFE2L2 and its consequences have been well documented in many cell types24. Identification of 
pathways and upstream regulators with known effects on keratinocyte differentiation and proliferative potential 
are intriguing. In particular, ROCK inhibitors have been shown to impact proliferative potential of keratino-
cytes25 and may contribute to the observed maintenance of colony forming efficiency by arsenite and antimo-
nite11. Both arsenite and antimonite also suppress keratinocyte differentiation10–13, which could be due to effects 
Figure 1. Comparison of effects of treatments on differentially expressed genes and proteins. Log fold change of 
genes (A) or proteins (C) differentially expressed by arsenite compared to control were plotted against log fold 
change of the same genes or proteins after antimonite treatment compared to control. Panel B shows genes with 
significantly different responses to arsenite and antimonite plotted as log RPKM. The upper line shows genes 
more responsive to antimonite, and the lower line shows genes more responsive to arsenite. Similarly, log fold 
changes of genes differentially expressed by arsenic compared to control were plotted against log fold changes of 
the same genes after treatments with cadmium chloride (D), potassium chromate (E) or sodium orthovanadate 
(F). Data were derived from next generation sequencing (A–C) or DNA microarray (D–F).
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on many of these upstream regulators with demonstrated roles in this process. Among these are Myc, the ephrin 
signaling system (including the ligand family, EFNA, and receptor families, EPHA and EPHB), GLI2, retinoic 
acid receptors and ligands (including isotretinoin), corticosteroids (including dexamethasone) and OSM.
experimental evidence for oncostatin M as an upstream regulator. Since OSM is the top predicted 
upstream regulator of transcriptional changes induced by arsenite and antimonite, experiments were designed to 
determine whether treatment of cells with OSM would elicit responses similar to those observed after treatment 
Pathway p-value As p-value Sb Overlap As Overlap Sb
A. Transcriptional Analysis
Nrf2-mediated Oxidative Stress Response 2.54E-10 3.76E-11 21/193 10.9% 27/193 14%
Glucocorticoid Receptor Signaling 4.69E-05 1.60E-05 19/339 5.6% 26/339 7.7%
Retinoate Biosynthesis I 4.71E-05 not listed 6/34 17.6% (4/34 11.7%)
Xenobiotic Metabolism Signaling 6.74E-05 2.33E-06 17/290 5.9% 25/290 8.6%
γ-Glutamyl Cycle 1.26E-04 4.04E-05 4/14 28.6% 5/14 35.7%
Vitamin C Transport (1.64E-04) 8.38E-05 (4/16 25.0%) 5/16 31.2%
B. Proteomic Analysis
Nrf2-mediated Oxidative Stress Response 4.24E-06 1.34E-04 8/193 4.1% 7/193 3.6%
Pentose Phosphate Pathway 1.26E-05 2.21E-05 3/10 30% 3/10 30%
Caveolar-mediated Endocytosis Signaling 2.34E-05 (8.13E-03) 5/71 7% (3/71 4.2%)
Integrin Signaling 9.05E-05 (8.38E-02) 7/219 3.2% (4/219 1.8%)
Pentose Phosphate Pathway (Non-oxidative) 3.38E-04 (4.91E-04) 2/6 33.3% (2/6 33.3%)
Methylglyoxal Degradation III (2.62E-03) 1.00E-04 (2/16 12.5%) 3/16 18.8%
Aldosterone Signaling in Epithelial Cells (8.44E-03) 5.20E-05 (4/166 2.4%) 7/166 4.2%
Glutathione Biosynthesis (1.43E-02) 9.93E-05 (1/3 33.3%) 2/3 66.7%
Table 1. Canonical pathways enriched for genes affected by arsenite and antimonite. Summary of the merged 
top five canonical pathways predicted by IPA to be affected by arsenite (As) and antimonite (Sb) treatments, 
sorted by p-values for analysis of untreated vs. arsenite-treated samples, which are shown in the first column. 
The second column shows p-values for analysis of untreated vs. antimonite-treated samples. The top five 
predicted pathways did not overlap completely for arsenite and antimonite treated samples. When a canonical 
pathway was predicted to be affected, but was not in the list of the top five, p-values are shown in parentheses. 
The third and fourth columns show the overlaps of differentially expressed genes or proteins with the molecules 
in the pathway and as a percentage. Part A are predictions based on transcriptional analysis of differentially 
expressed genes and Part B are predictions based on proteomic analysis.
Regulator p-value As p-value Sb Prediction
A. Transcriptional Analysis
OSM 1.56E-24 5.72E-23 Activated by Sb
Dexamethasone 7.18E-23 7.99E-26 No prediction
NFE2L2 2.73E-21 6.96E-21 Activated by As and Sb
TNFα 1.78E-17 3.83E-21 Activated by Sb
Arsenic trioxide 1.57E-16 (1.70E-11) Activated by As and Sb
MYC (1.18E-13) 9.57E-18 No prediction
B. Proteomic Analysis
MYC 2.83E-16 3.44E-19 No prediction
ROCK2 5.04E-16 3.47E-15 Inhibited by As and Sb
FOS 1.09E-14 (4.40E-11) No prediction
JUN 3.35E-13 (7.96E-10) No prediction
EFNA4 3.38E-13 5.84E-16 Inhibited by As and Sb
17-Beta-estradiol (1.09E-12) 9.14E-16 No prediction
EFNA3 (2.74E-11) 4.86E-14 Inhibited by As and Sb
Table 2. Predicted upstream regulators. Summary of IPA predicted upstream regulators based on differentially 
expressed genes (A) or proteins (B). The top five predicted upstream regulators are sorted by p-value for changes 
due to arsenite treatment (As), which are shown merged in the first column. The second column shows p-values 
for analysis of untreated vs. antimonite-treated samples (Sb). The top five predicted upstream regulators did not 
overlap completely for arsenite and antimonite treated samples. When a regulator was predicted, but was not 
in the list of the top five, p-values are shown in parentheses. The last column indicates whether the regulator is 
predicted to be activated or inhibited or whether no prediction was made.
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with arsenite and antimonite, especially effects on differentiation and proliferative potential. Because we have 
been investigating effects of chronic treatment (days rather than hours) with arsenite and antimonite, we used 
similar treatment times for our experiments with OSM, with treatments starting at confluence, just as the cells 
begin differentiating.
Like arsenite and antimonite, OSM treatment had a large inhibitory effect on induction of a subset of differen-
tiation markers: KRT1, KRT10, DSG1, DSC1, LOR and FLG mRNAs (Fig. 2). Although arsenite and antimonite 
have substantial effects on these mRNAs, OSM is a better suppressor than either arsenite or antimonite for several 
of these. In contrast to arsenite and antimonite, OSM had only a modest effect on levels of IVL mRNA, while 
increasing TGM1 mRNA. Finally, like arsenite and antimonite11, chronic OSM treatment increased the prolifer-
ative potential of cultured keratinocytes after confluence compared to untreated cultures as measured by colony 
forming efficiency (Fig. 3, dark bars).
OSM has been demonstrated to act through Stat signaling (Stats 1 and 3) and Erk signaling pathways (reviewed 
by26). Chronic exposure of keratinocytes to OSM increased phospho-Stat1, -Stat3, and -Erk, as expected (Fig. 4A). 
Arsenite or antimonite treatments alone had no effect on Stat1 or Stat3 phosphorylation while they stimulated 
Erk phosphorylation. Simultaneous treatment with OSM and arsenite or antimonite decreased Stat1 phosphoryl-
ation compared to OSM alone and had little impact on OSM-induced Stat3 or Erk phosphorylation.
This result raises the question of which signaling pathways are required for suppression of differentiation 
marker expression and increase in proliferative potential by arsenite, antimonite and OSM. Inhibition of the Jak 
kinases, responsible for Stat phosphorylation, was partially able to reverse decreases in differentiation markers 
by OSM. Inhibition of the kinase that phosphorylates Erk had only a small effect, but the combination of the two 
inhibitors completely blocked OSM effects. In contrast, only an inhibitor of Erk phosphorylation affected the 
response to arsenite and antimonite (Supplementary Table S4). A plausible reason why OSM had a larger impact 
than arsenite and antimonite on a subset of differentiation markers might be due to independent, negative effects 
of both Stat and Erk signaling pathways on expression of the affected genes. OSM signals through both Stat and 
Erk pathways, while arsenite and antimonite signal only through Erk. In contrast to inhibitor effects on differ-
entiation markers, only an Erk pathway inhibitor blocked the increased proliferative potential elicited by both 
arsenite and OSM (Fig. 3, vertically vs horizontally striped bars).
impact of corticosteroid signaling on responses to arsenite and antimonite. The prediction of 
dexamethasone as an upstream regulator suggests that responses to arsenite and antimonite may be different in 
the presence and absence of corticosteroids. Under standard culture conditions, arsenic oxides have been shown 
to suppress various markers of differentiation27. Responses to antimonite are similar (Fig. 5A). Present work 
demonstrates that suppression of several differentiation markers by both arsenite and antimonite was diminished 
by addition of hydrocortisone, the major steroid in the culture medium. The differences in the ratios of suppres-
sion in the presence and absence of hydrocortisone ranged from several hundred fold down to two fold (Fig. 5B). 
Most dramatically affected were KRT1, KRT10 and DSG1. For these genes, hydrocortisone alone did not greatly 
affect amounts of mRNAs, but instead diminished the responses to arsenite and antimonite. For another set of 
genes (FLG, LOR and IVL), the fold suppression by arsenite and antimonite was altered, but this was predomi-
nantly due to changes induced by hydrocortisone alone. The suppressive effects of corticosteroids on these genes 
have also been observed in vivo28. For all of these genes, hydrocortisone affected the responses to arsenite and 
antimonite similarly. Responses to dexamethasone were similar to those obtained with hydrocortisone.
impact of arsenite and antimonite on ephrins, predicted upstream regulators. Since ephrins and 
their receptors have significant impacts on keratinocyte differentiation (reviewed by29) and were identified by IPA 
Figure 2. Suppression of differentiation marker expression by arsenite (As), antimonite (Sb) and oncostatin M 
(OSM). Relative mRNA amounts were determined by qPCR and normalized to amounts in untreated samples, 
set at 1. Results are the averages and ranges of two samples. Most treated samples are significantly different from 
the untreated control at p ≤ 0.001; IVL treated with OSM and TGM1 treated with Sb have p values of 0.035.
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as upstream regulators after arsenite and antimonite treatment, we examined effects of arsenite and antimonite on 
levels of ephrin and ephrin receptor mRNA expression. Seven ephrin mRNAs and seven ephrin receptor mRNAs 
were expressed at moderate levels (>1 RPKM). Three ephrin receptor mRNAs (EPHA1, EPHA2 and EPHA4) and 
one ephrin mRNA (EFNB2) were decreased two fold or more by arsenite. These decreased receptor mRNAs led to 
decreases in the encoded proteins by both arsenite and antimonite as demonstrated by Western blotting (Fig. 4B). 
OSM, which also had suppressive effects on a subset of the differentiation markers affected by arsenite and anti-
monite, decreased EphA1 and EphA4 while increasing EphA2. Effects of OSM on EphA2 have been previously 
reported30. The number of different ephrin receptors and their abilities to bind many or all of the ligands in their 
class (A or B) makes ascribing particular functions to individual receptors difficult. While responses to particular 
ephrins are largely overlapping, some differences have been demonstrated22, suggesting that receptors distinguish 
among the ligands and initiate different downstream signaling. Perhaps EphA2 is of particular importance for 
regulation of TGM1, which was suppressed by arsenite and antimonite, but increased by OSM, while regulation 
of KRT1, KRT10, DSG1 and DSC1, which were decreased by all three agents, may be under the control of EphA1 
and/or EphA4. All of these markers have been shown to be in the set of ephrin up-regulated genes22.
predicted regulation of transcription factors by arsenite and antimonite. The IPA prediction of 
upstream regulators that might be affected by arsenite and antimonite relies on analysis of the patterns of gene expres-
sion observed after treatment. An alternative approach to explain some of the transcriptional effects of these treatments 
is to identify transcription factors that are themselves altered by treatment (regardless whether they are primary tar-
gets). To this end, we filtered the gene expression data for transcription factors that were differentially expressed at the 
statistical significance of p ≤ 0.05. Supplementary Table S5 presents the transcription factors altered by arsenite treat-
ment. Of the 30 factors identified, 24 are also altered by antimonite at a similar level of statistical significance. Twelve of 
these 30 transcription factors have been demonstrated to affect keratinocyte differentiation (IRF6, EHF, TP63, KLF5, 
CEBPA, BARX2, FOXQ1, HOPX, FOS, GRHL1, ELF3 and PITX1) while nine have been shown to affect proliferative 
potential of cells (IRF6, EHF, BTG2, TP63, KLF5, CEBPA, CDKN2B, HOPX and ELF3)31–51.
A network of this first group of transcription factors, demonstrating predicted regulation of several down-
stream differentiation markers, is shown in Fig. 6A. Also included are NOTCH1 and FOXN1, shown previously 
to regulate keratinocyte differentiation. Major hubs occur with TP63, CEPBA, NOTCH1, FOXN1 and JUN/FOS. 
Most of the transcription factors connect directly to the differentiation marker genes or connect through one 
intermediate transcription factor. These are not all of the possible connections, but represent the most direct paths 
between transcription factors and their targets. A separate network illustrating possible regulation of differenti-
ation marker expression by FOXQ1 is shown in Fig. 6B. The connection of FOXQ1 to downstream targets is less 
direct, involving more intermediates. These two networks, based on evidence gleaned from the literature, support 
the hypothesis that these transcription factors, shown to be altered by arsenite and antimonite treatment, could 
be responsible, for much of the down-regulation of differentiation markers by these agents.
Figure 3. Stimulation of colony formation by arsenite and oncostatin M (OSM). Values for colony forming 
efficiency (CFE) from triplicate cultures are given relative to no treatment (NT) or treatment with 2 µM 
arsenite (As) or 50 ng/ml OSM. Effects of inhibitors of the Erk (U1026, 10 µM) and Stat (Jak Kinase inhibitor 
1, 1 µM) pathways are indicated (ERK inh, STAT inh). A representative result is shown. In a compilation of 
2–6 experiments with various combinations of conditions, stimulation of CFE compared to NT was highly 
significant for As and OSM (†p < 0.02) and inhibition of CFE by the Erk inhibitor (*p < 0.02).
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Discussion
Examination of affected canonical pathways revealed that many of the same differentially expressed genes led 
to the predicted perturbation of the top pathways, suggesting connections among these pathways. Among sev-
eral compounds that induce Nrf2-mediated oxidative stress response in keratinocytes, judging by their abilities 
Figure 4. Analysis of treatment effects by immunoblotting. (A) Effects of arsenite (As), antimonite (Sb) and OSM 
on signaling pathways. SIK cultures were treated at confluence for 7 days with 3 µM arsenite, 6 µM antimonite, 
50 ng/ml OSM or combinations as indicated, then harvested for immunoblotting with the indicated antibodies. 
(B) Alteration of ephrin receptor levels by arsenite (As), antimonite (Sb) and OSM. SIK cultures were treated at 
confluence for 6 days with 3 µM arsenite, 6 µM antimonite or 50 ng/ml OSM, then harvested for immunoblotting. 
For panel A, the same set of treated cell extracts was run on parallel gels, blotted and probed with the indicated 
antibodies. For panel B, a different set of cell extracts was run on parallel gels, blotted and blotted probed for the 
ephrins. Original images of the blots and molecular weight markers are shown in Supplementary Figure 4 from 
which the relevant areas of interest were cropped (separated by horizontal lines above).
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to induce HO1, only arsenite and antimonite induce a robust and sustained response15. Perhaps this sustained 
response helps rationalize their unique abilities to suppress keratinocyte differentiation while maintaining prolif-
erative potential. However, hyperactivation of a single signaling pathway could produce a contrasting result. For 
example, unopposed activity of the Nrf2-mediated oxidative stress response by KEAP1 ablation leads to epider-
mal hyperkeratosis and increased expression of keratinocyte differentiation markers in mice52.
The lists of top upstream regulators predicted by transcriptional and proteomic analysis are intriguing and pro-
vide some validation of the predictive process. That arsenic trioxide is predicted to be activated by both arsenite and 
antimonite is especially supportive. Most of the other regulators have already been identified as important regulators 
of keratinocyte differentiation and proliferative potential. OSM, ephrins (e.g. EFNA3 and EFNA4) and dexametha-
sone all have been demonstrated to affect transcription of differentiation markers22,28,30, while MYC has been shown 
to drive cells from the stem cell compartment and initiate the differentiation process53. FOS and JUN have been 
identified as transcription factors important for expression of several keratinocyte differentiation markers, reviewed 
in54. Finally ROCK inhibitors prolong the proliferative capacity of cultured keratinocytes25. The predicted inhibition 
of ROCK2 by arsenite and antimonite could rationalize their abilities to maintain proliferative potential.
Three of the predicted upstream regulators have been experimentally validated. First, OSM, predicted to be acti-
vated by antimonite, did indeed demonstrate many similarities to arsenite and antimonite. All three agents effectively 
suppressed a subset of differentiation markers while maintaining proliferative potential. Second, corticosteroid ago-
nists such as dexamethasone and the endogenous agonist hydrocortisone acted similarly to arsenite and antimonite 
by suppressing FLG, LOR and IVL expression (effects on FLG and LOR previously reported by28) while antagonizing 
arsenite and antimonite suppression of several other differentiation markers. These mixed responses are consistent 
with a z-score that predicted neither activation nor inhibition. Finally, ephrins and their receptors have been shown to 
promote keratinocyte differentiation22 and were predicted upstream regulators of arsenite and antimonite downstream 
effects. We have shown here that amounts of several ephrin receptors were decreased by these metalloids.
conclusions
Based on transcriptional and proteomic comparisons and Ingenuity pathway analysis, showing that keratinocytes 
respond nearly identically, we conclude that arsenite and antimonite share virtually the same signaling pathways. 
Evidently, three unanticipated upstream regulators, verified here experimentally, participate in the response. In 
addition, several transcription factors appear affected by arsenite and antimonite, and a model network showing 
Figure 5. Effect of hydrocortisone (HC) on transcriptional responses to arsenite (As) and antimonite (Sb) 
treatments. (A) Relative mRNA amounts were determined by qPCR and normalized to amounts in samples 
without HC, set at 100%. Results are the means and standard deviations of 3 samples. (B) Ratios were calculated 
for treatments in the presence of hydrocortisone compared to those in the absence of hydrocortisone. 
Hydrocortisone significantly altered the response at p ≤ 0.05 except for the following: FLG in samples treated 
with As, and IVL in samples treated with As and Sb.
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how these affect differentiation markers has been constructed. A goal of future efforts will be to connect affected 
transcription factors with signaling pathways and ultimately with direct targets of arsenite and antimonite. Thus, 
present results emphasize the likelihood arsenite and antimonite act in parallel as human skin carcinogens.
Materials and Methods
Sample preparation for transcriptomic and proteomic analyses. These experiments used a line of 
spontaneously immortalized epidermal keratinocytes (SIK)55. The cells were cultured as previously described, 
under which conditions normal and neoplastic human keratinocyte lines exhibit highly similar responses to arse-
nic treatment, and normal human keratinocytes give qualitatively the same patterns of gene expression at different 
concentrations of arsenic and different time points15. Cultures were treated with similarly effective concentra-
tions of sodium arsenite (3 µM) and potassium antimony tartrate (6 µM), as shown previously for transcriptional 
responses and confirmed in this work for survival (Supplementary Fig. S2). Near the maximally tolerated con-
centrations for the 7 day exposure period, while approximating exposures of ≈200 ppb commonly found in well 
water in geographical regions at risk56, this treatment maximized the transcriptional responses. Sample prepara-
tion, library synthesis (using a TruSeq RNA Sample Prep Kit from Illumina, Inc), transcriptomic analysis using 
RNA-Sequencing technology and proteomic analyses were performed as described14; to permit accurate signaling 
pathways analysis, two additional experiments were processed to add to the two previously analyzed. Thus a total 
of 12 samples, four each from untreated control (n = 4), arsenite-treated (n = 4) and antimonite-treated (n = 4) 
human epidermal keratinocyte cultures, were analyzed by RNA-sequencing. Each of the four pairs of arsenite and 
antimonite-treated samples, along with the untreated control, was derived from a separate experiment performed 
at different times. An average of 35 million sequence reads was obtained for each individual sample. These were 
assembled and mapped to the annotated human genome assembly (release 80). In all samples, ~90% (88–91%) of 
the reads were mapped to the human reference sequence. Differential gene expression analysis between untreated 
(control) and treated (arsenite or antimonite) human epidermal keratinocytes was performed by t-testing with 
correction for false discovery rate.
For access to original transcriptional data, the sequencing results (4 samples each of untreated, As-treated 
and Sb-treated cultures) have been deposited into the NCBI SRA repository (Temporary Submission ID: 
Figure 6. IPA generated networks of transcription factors and differentiation markers. (A,B) Custom IPA 
networks were generated from selected lists of keratinocyte differentiation markers and transcription factors 
shown by transcriptional analysis to be altered by arsenite and antimonite treatments. Molecules in green were 
decreased in the datasets with darker shades indicating more suppression. Molecules in pink were increased 
in the dataset. Blue lines are predicted to lead to inhibition and orange lines to activation. Yellow lines indicate 
findings opposite to predictions, while black lines indicate no prediction of activation or suppression. The 
networks were generated through the use of Ingenuity Pathway Analysis version 2018 (QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis)62.
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SUB4618061) with accession #PRJNA510150. For access to the original proteomic data, the raw data were depos-
ited in the Massive Proteomics repository (massive.ucsd.edu ID #MSV000082992) and ProteomeExchange http://
proteomecentral.proteomexchange.org (ID # PXD011259).
ingenuity pathway analysis. Transcriptomic datasets comparing arsenite or antimonite treated samples 
to untreated samples were uploaded into the Qiagen Ingenuity Pathway Analysis program. Core analysis was 
performed, filtering for fold change ≥2, expression intensity (RPKM) ≥0.2 and false discovery rate ≤ 0.2.
DnA microarray. SIK cultures were treated starting just before confluence and harvested for analysis after 10 
days of treatment with 1 µM sodium arsenite, 3 µM sodium arsenate, 10 µM cadmium chloride, 5 µM potassium 
chromate or 10 µM sodium vanadate, maximally tolerated concentrations that produced equivalent suppression 
of differentiation (involucrin mRNA level). cDNA was synthesized using total RNA with oligo dT priming fol-
lowed by second strand RNA synthesis using biotin-labeled nucleotides as previously described15. Fragmented 
cRNA was hybridized to U-133A arrays (Affymetrix, Santa Clara, CA), and the hybridization was detected with 
streptavidin-labeled phycoerythrin. After measurement of hybridization intensities, the.CEL files were imported 
into an R language environment using Bioconductor software and subjected to quantile normalization. An arith-
metic average of 16 normalized intensity values from PM probes were transformed using the general logarithm 
transformation (glog)57. The processed data are available in the Dryad Digital Repository (https://doi.org/10.5061/
dryad.t4q2nc8). Prior to analysis, probes with present calls in fewer than 2 samples were filtered, leaving 11,952 
probes. Differential expression analyses were conducted using the Bioconductor package limma, version 3.38.358, 
with expression modeled by group using a single factor linear model. The analysis incorporated variance weights for 
log expression calculated using the function vooma within limma59. Analyses were conducted using R, version 3.5.3 
(R Core Team, 2019). Each treatment was analyzed in two independent cultures. The duplicates of arsenic consisted 
of one arsenite and one arsenate culture, previously shown to be equivalent in transcription15. A multi-dimensional 
scaling plot of the results showed that the arsenic samples were well separated from the cadmium, chromate and 
vanadate samples, but the last two were not clearly separated from each other (Supplementary Fig. S3). The number 
of differentially expressed probes (with false discovery rate adjusted p < 0.05) between each treatment and control 
was 1036 (arsenic), 808 (cadmium), 184 (chromate) and 522 (vanadate).
Real time pcR. SIK cultures were treated at confluence with 50 ng/ml Oncostatin M (OSM) (R&D Systems), 
3 µM sodium arsenite, 6 µM potassium antimony tartrate (antimonite) or not treated. In some experiments cell 
cultures were pretreated for 30 min with 10 µM U1026 (an inhibitor of MEK1 and MEK2) (LC Laboratories) 
or 1 µM JAK Inhibitor I (Calbiochem) before addition of OSM, arsenite or antimonite. To test the influence 
of hydrocortisone on arsenite or antimonite effects, SIK cultures were grown to confluence in normal culture 
medium, then switched to medium containing serum depleted of steroids by charcoal/dextran treatment60 in the 
presence and absence of combinations of 10 µM hydrocortisone, 3 µM arsenite and 6 µM antimonite. RNA was 
prepared using Trizol reagent (Life Technologies), followed by cDNA preparation using an Applied Biosystems 
reverse transcription kit. cDNA was analyzed by qPCR with Taqman assays (Applied Biosystems), normalizing to 
MAPK1, a gene product demonstrated by transcriptomic analysis not to be changed by arsenite and antimonite 
treatments.
immunoblotting. Immunoblotting was performed as described2 with antibodies obtained from Cell 
Signaling Technologies: EphA1 (rabbit monoclonal D6V71), EphA2 (rabbit monoclonal D4A2), EphA3/A4/A5 
(rabbit monoclonal D2C11), Erk1/2 (rabbit monoclonal 137F5), phospho-Erk1/2 (rabbit monoclonal 20G11), 
Stat1 (rabbit monoclonal 43H3), phospho-Stat1 (rabbit monoclonal D4A7), Stat3 (rabbit monoclonal D3Z2G), 
phospho-Stat3 (rabbit monoclonal D3A7) and cleaved Notch1 (rabbit monoclonal D3B8). Antibodies were used 
at a 1:1000 dilution of the supplied stock following the protocols specified by the supplier. Blots were developed 
using Thermo Fisher ECL Plus and visualized with a My ECL imager. Image acquisition time was adjusted to visu-
alize all bands without saturating the brightest bands (from 30 seconds to 30 minutes depending on the efficacy of 
the antibody). Data were analyzed using Thermo My Image Analysis software, version 2.0. Images were inverted 
to display dark bands on a light background and in some cases brightness or contrast were adjusted to show 
lighter bands more distinctly, again without saturating the darkest bands. Images were then cropped, arranged 
and converted to TIFs with Photoshop, version CS6.
Colony forming efficiency. Confluent SIK cultures were untreated or treated with 50 ng/ml OSM or 3 µM 
arsenite in the presence and absence of 10 µM U1026 or 1 µM JAK Inhibitor I. After 9 days, cells were trypsinized, 
counted and 3000 cells from each sample were inoculated on 6 cm dishes in the presence of irradiated 3T3 feeder 
cells. Cultures were grown for 2 weeks, when most colonies were 2–5 mm in diameter. After fixation and staining 
with Rhodanile blue61, colonies of approximately 50 cells or more were counted. Results were normalized to the 
untreated sample. The experiment was performed in triplicate.
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